CVRx reveals 20% revenue growth and trial milestone in preliminary Q1 2026 update
CVRx (NASDAQ:CVRX), a commercial-stage medical device company specializing in neuromodulation for cardiovascular disease, reported on April 13, 2026, preliminary revenue growth of approximately 20% for the first quarter.










